Viking Therapeutics bets it can chip away at Eli Lilly’s and Novo Nordisk’s weight-loss stronghold

Eli Lilly’s and Novo Nordisk’s obesity franchises face a new kind of competition, one that is coming less from the biggest drugmakers and more from a specialist biotech seeking to prove that it can matter in a market dominated by GLP-1 style therapies. A recent market report pointed to Viking Therapeutics as a “dark-horse” candidate, arguing that it aspires to take share from the companies currently setting the pace for weight-loss treatment adoption.

The thrust of the argument is strategic rather than incremental. Instead of competing only as a follower to established regimens, Viking is framed as aiming to become an alternative for patients and prescribers already benefiting from therapies from Eli Lilly and Novo Nordisk. If the company can demonstrate meaningful clinical performance and practical advantages, the report suggests that it could convert attention into prescriptions.

The report also highlights how the obesity category has become a battleground not just for efficacy, but for differentiation that can survive payer scrutiny. In practical terms, that means companies are competing on outcomes, dosing convenience, and the overall “value proposition” for insurers and health systems, because those buyers shape which drugs remain accessible at scale.

For Eli Lilly, the headline risk is concentration: if physicians and payers decide there are credible options beyond the incumbents, even modest shifts in demand can pressure growth expectations. For Novo Nordisk, the same logic applies, especially given how quickly the competitive field is expanding as more obesity candidates move through trials and seek regulatory and commercial traction.

Viking’s pitch, as characterized in the report, is that it may not need to be a direct replica of the leading GLP-1 narratives to take a meaningful slice of the market. The implicit bet is that patients and clinicians could prefer a therapy that offers a distinct clinical profile, supporting a new set of prescribing habits.

Still, the market piece does not provide fresh trial readouts, regulatory updates, or commercial sales figures that would let readers verify the degree of progress behind Viking’s ambition. It also does not outline specific endpoints or timelines in the text provided for this review, so it is best read as a forward-looking competitive framing rather than a disclosure of new, decision-grade developments.

From a sector perspective, the story fits a broader pattern in healthcare: when a therapeutic category becomes commercially massive, investors and drug developers increasingly back strategies that could disrupt the incumbents’ dominant positions. In obesity, where demand growth has been fast, the market can reward companies that show they can translate clinical promise into real-world access.

What to watch next is therefore not just whether Viking advances its program, but whether it can produce credible evidence tied to payer-relevant outcomes, and whether any regulatory milestones convert into a commercial rollout that is scalable. For Eli Lilly, the near-term focus remains on defending its own growth as challengers attempt to demonstrate why patients should switch or diversify their treatment choices. For Novo Nordisk, the competitive question is whether any new entrants can move beyond attention and into sustained prescribing.